Efficacy of PI3K inhibitors in advanced breast cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

Palbociclib and letrozole in advanced breast cancer

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · see citing works

The PI3K Pathway in Human Disease

Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · see citing works

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827 · see citing works

The emerging mechanisms of isoform-specific PI3K signalling

Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · see citing works

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744 · see citing works

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

Simoncini, T., Hafezi‐Moghadam, A., Brazil, D. P., Ley, K. F., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,437 · see citing works

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,291 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001 · see citing works

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877 · see citing works

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837 · see citing works

PI3K in lymphocyte development, differentiation and activation

Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1056 · Cited by 812 · see citing works

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 768 · see citing works

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Folkes, A. J., Ahmadi, K., ALDERTON, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 756 · see citing works

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 745 · see citing works

Genomic characterization of metastatic breast cancers

Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N. M., Piscuoglio, S., Carbuccia, N., Soria, J., Dien, A. T., Adnani, Y., Kamal, M. T., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 715 · see citing works

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S., Zhang, J., Signoretti, S., Loda, M. F., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 691 · see citing works

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650 · see citing works

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · see citing works

PI 3-kinase p110β: a new target for antithrombotic therapy

Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V. B., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 582 · see citing works

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

Miller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555 · see citing works

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Maira, S.-M., Pecchi, S., Huang, A., Burger, M. T., Knapp, M. S., Sterker, D., Schnell, C., Guthy, D. A., Nagel, T., Wiesmann, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 533 · see citing works

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 529 · see citing works

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

Graupera, M., Guillermet‐Guibert, J., Foukas, L. C., Phng, L., Cain, R. J., Salpekar, A., Pearce, W. P., Meek, S. E., Millán, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 521 · see citing works

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Fritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504 · see citing works

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 494 · see citing works

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · see citing works

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Dienstmann, R., Rodon, J. A., Serra, V., & Tabernero, J. M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 464 · see citing works

Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation

Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463 · see citing works

Signalling by PI3K isoforms: insights from gene-targeted mice

Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., & Foukas, L. C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.02.008 · Cited by 450 · see citing works

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · see citing works

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

Juric, D., Rodon, J. A., Tabernero, J. M., Jankú, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J. D., Schüler, M., Gil-Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 436 · see citing works

p110δ, a novel phosphoinositide 3-kinase in leukocytes

Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R. C., Warne, P. H., Zvelebil, M., Higashi, K., Volinia, S., Downward, J., & Waterfield, M. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4330 · Cited by 434 · see citing works

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

Kalinsky, K. M., Jacks, L. M., Heguy, A., Patil, S. N., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D. B., Gerald, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401 · see citing works

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1897 · Cited by 396 · see citing works

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Leo, A. D., Johnston, S. R. D., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R. M., Mouret‐Reynier, M., Kalev, D. N., Egle, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 382 · see citing works

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

Baselga, J. M., Cortés, J., Im, S., Clark, E., Ross, G. A., Kiermaier, A. C., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364 · see citing works

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Sarker, D., Ang, J. E., Baird, R. D., Kristeleit, R. S., Shah, K. J., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G. G., Ware, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 361 · see citing works

Targeting the PI3-kinase pathway in triple-negative breast cancer

Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 330 · see citing works

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Mosele, F., Stefanovska, B., Lusque, A., Dien, A. T., Garberis, I., Droin, N. M., Tourneau, C. L., Sablin, M., Lacroix, L., Enrico, D. H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.006 · Cited by 316 · see citing works

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S. A., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 310 · see citing works

PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality

López‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24831 · Cited by 302 · see citing works

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M. N., Johnston, S. R. D., Morales, S. M., Yardley, D. A., Melichar, B., Forero, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295 · see citing works

Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development

Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H., et al. (2008) · Science Signaling · doi:10.1126/scisignal.1161577 · Cited by 270 · see citing works

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Juric, D., Jankú, F., Rodon, J. A., Burris, H. A., Mayer, I. A., Schüler, M., Seggewiß-Bernhardt, R., Gil-Martín, M., Middleton, M. R., Baselga, J. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 247 · see citing works

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Yang, S. X., Polley, E. C., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 239 · see citing works

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Loibl, S., Majewski, I. J., Guarneri, V., Nekljudova, V., Holmes, E. M., Bria, E., Denkert, C., Schem, C., Sotiriou, C. P., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 230 · see citing works

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Baselga, J. M., Phillips, G. D. L., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., & Pegram, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2499 · Cited by 229 · see citing works

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

Barok, M., Tanner, M., Köninki, K., & Isola, J. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226 · see citing works

Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203 · see citing works

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquière, N., Bradley, E. K., Bull, R., Do, S., Dotson, J., Dudley, D. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 182 · see citing works

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Martín, M., Chan, A., Dirix, L. Y., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M. I., Криворотько, П. В., López, N. B., Campone, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180 · see citing works

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., den Abbeele, A. D. V., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 176 · see citing works

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Juric, D., Krop, I. E., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Bohorquez, S. M. S., Savage, H. M., Sampath, D., Salphati, L., Lin, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1080 · Cited by 161 · see citing works

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 151 · see citing works

Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation

Sopasakis, V. R., Liu, P., Suzuki, R., Kondo, T., Winnay, J. N., Tran, T. T., Asano, T., Smyth, G., Sajan, M. P., Farese, R. V., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.002 · Cited by 148 · see citing works

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

Miller, B. W., Przepiorka, D., de Claro, R. A., Lee, K., Nie, L., Simpson, N. E., Gudi, R., Saber, H., Shord, S. S., Bullock, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2522 · Cited by 147 · see citing works

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138 · see citing works

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab

Jensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 136 · see citing works

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Ellis, M. J., Li, L., Crowder, R. J., Yu, T., Hoog, J., Snider, J., Davies, S. R., DeSchryver, K., Evans, D. B., Steinseifer, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0575-y · Cited by 130 · see citing works

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 116 · see citing works

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)

Loibl, S., de la Peña, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C., Rezai, M., Bermejo, B., Untch, M., Lee, S. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.020 · Cited by 102 · see citing works

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Mayer, I. A., Prat, A., Egle, D., Blau, S. H., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M. A., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 99 · see citing works

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P. G., Ballestrero, A., Dubsky, P. C., Lombard, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30334-1 · Cited by 98 · see citing works

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Ma, C. X., Luo, J. R., Naughton, M., Ademuyiwa, F. O., Suresh, R., Griffith, M., Griffith, O. L., Skidmore, Z. L., Spies, N. C., Ramu, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1745 · Cited by 96 · see citing works

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 92 · see citing works

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Allevi, G., Strina, C., Andreis, D., Zanoni, V., Bazzola, L., Bonardi, S., Foroni, C., Milani, M., Cappelletti, M. R., Gussago, F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.151 · Cited by 85 · see citing works

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Rodrigues, D. A., Sagrillo, F. S., & Fraga, C. A. M. (2019) · Pharmaceuticals · doi:10.3390/ph12020069 · Cited by 83 · see citing works

Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis

Pang, B., Cheng, S., Sun, S., An, C., Liu, Z., Xue, F., & Liu, G. (2014) · Scientific Reports · doi:10.1038/srep06255 · Cited by 81 · see citing works

The PI 3-kinase isoforms p110α and p110β have differential roles in PDGF- and insulin-mediated signaling

Hooshmand-Rad, R., Hájková, L., Klint, P., Karlsson, R., Vanhaesebroeck, B., Claesson, L., & Heldin, C. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.2.207 · Cited by 79 · see citing works

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Juric, D., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H., Iwata, H., Conte, P., Mayer, I., Kaufman, B., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs3-08 · Cited by 62 · see citing works

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

Guérin, M., Rezaï, K., Isambert, N., Campone, M., Autret, A., Pakradouni, J., Provansal, M., Camerlo, J., Sabatier, R., Bertucci, F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.025 · Cited by 62 · see citing works

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A. H., Bachelot, T., Chan, S. Y. T., Han, H. S., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 62 · see citing works

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer

Guarneri, V., Generali, D., Frassoldati, A., Artioli, F., Boni, C., Cavanna, L., Tagliafico, E., Maiorana, A., Bottini, A., Cagossi, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4737 · Cited by 61 · see citing works

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

Mensah, F., Blaize, J.-P., & Bryan, L. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s142264 · Cited by 50 · see citing works

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies

Cortés, J., Im, S., Holgado, E., Pérez-García, J. M., Schmid, P., & Chávez‐MacGregor, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.011 · Cited by 49 · see citing works

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

Juric, D., Krop, I. E., Ramanathan, R. K., Xiao, J. J., Sanabria, S., Wilson, T. R., Choi, Y., Parmar, H. R., Hsu, J. Y., Baselga, J. M., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-64 · Cited by 43 · see citing works

Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

Juric, D., Ismail-Khan, R. R., Campone, M., García‐Estévez, L., Becerra, C., Boer, R. D., Hamilton, E. P., Mayer, I. A., Hui, R., Lathrop, K., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p3-14-01 · Cited by 37 · see citing works

Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies

Hong, R., Edgar, K. A., Song, K., Steven, S., Young, A. E., Hamilton, P., Arrazate, A., de la Cruz, C., Chan, C., Pang, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd4-14 · Cited by 27 · see citing works

PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis

Shao, Z.-M., Liu, Y., Jiang, Y., Yu, K., & Zuo, W. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60115 · Cited by 25 · see citing works

Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.

Razavi, P., dos Anjos, C. H., Brown, D. N., Li, Q., Ping, C., Herbert, J., Colon, J., Liu, D., Mao, M., Norton, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1009 · Cited by 17 · see citing works

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

Olivero, A. G., Heffron, T. P., Baumgardner, M., Belvin, M. P., Ross, L. B., Blaquière, N., Bradley, E. K., Castanedo, G. M., Derynck, M. K., Do, S., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-ddt02-01 · Cited by 15 · see citing works

PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis

Liu, Y.-R., Jiang, Y.-Z., Zuo, W.-J., Yu, K.-D., & Shao, Z.-M. (2014) · Dove Medical Press (Taylor and Francis Group) · Cited by 11 · see citing works

Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.

Wainberg, Z. A., Shapiro, G. I., Curigliano, G., Kristeleit, R. S., Leong, S., Alsina, M., Milella, M., Britten, C. D., Gelmon, K. A., Olszanski, A. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2566 · Cited by 9 · see citing works

Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models

Fiascarelli, A., Merlino, G., Capano, S., Paoli, A., Bressan, A., Bigioni, M., Scaltriti, M., Arribas, J., Morales, C. B., Pellacani, A. U. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz268.065 · Cited by 9 · see citing works

Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal

Prendergast, G. C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3239 · Cited by 7 · see citing works

Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment

Condorelli, R., & André, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx218 · Cited by 7 · see citing works

Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)

Mosele, M. F., Lusque, A., Dien, A. T., Droin, N. M., Tourneau, C. L., Lacroix, L., Bièche, I., Massard, C., Bertucci, F., & André, F. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz100 · Cited by 7 · see citing works

Abstract A050: PIK3CA mutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2- ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies

Baselga, J. M., Sellami, D. B., El-Hashimy, M., Dharan, B., Wang, Y., Scheuer, N., Sankaran, B., & Leo, A. D. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-17-a050 · Cited by 5 · see citing works

Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors

Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Irrissuto, C., Pellacani, A. U. E., Scaltriti, M., & Binaschi, M. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2160 · Cited by 5 · see citing works

Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes?

Link, B. K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4234 · Cited by 4 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z., Kumar, A., vishakha, V., Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 563 · see citing works

PI3K inhibitors are finally coming of age

Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 487 · see citing works

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 383 · see citing works

Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance

Li, Y., Xu, Z., Ruan, S., Mo, S., Qin, J., & Cheng, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01219-0 · Cited by 330 · see citing works

Current State of Breast Cancer Diagnosis, Treatment, and Theranostics

Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 316 · see citing works

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Li, Q., Li, Z., Luo, T. L., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 274 · see citing works

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231 · see citing works

TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations

Liu, Q., & Xie, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 203 · see citing works

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

Zhu, K., Wu, Y. Q., He, P., Fan, Y. J., Zhong, X., Zheng, H. Y., & Luo, T. L. (2022) · Cells · doi:10.3390/cells11162508 · Cited by 190 · see citing works

Overview of recent advances in metastatic triple negative breast cancer

O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 138 · see citing works

Resistance and Overcoming Resistance in Breast Cancer

Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 136 · see citing works

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Fusco, N., Malapelle, U., Fassan, M., Marchiò, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P. G., Tos, A. P. D., Maiorano, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644737 · Cited by 121 · see citing works

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 123 · see citing works

Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer

Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119 · see citing works

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 123 · see citing works

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment

Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022) · Cancers · doi:10.3390/cancers14102424 · Cited by 121 · see citing works

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges

Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 115 · see citing works

Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction

Jiang, H., Li, M., Du, K., Ma, C., Cheng, Y., Wang, S., Nie, X., Fu, C., & He, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00539-7 · Cited by 112 · see citing works

Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity

Abdellatif, M., Trummer-Herbst, V., Heberle, A. M., Humnig, A., Pendl, T., Durand, S., Cerrato, G., Hofer, S. J., Islam, M., Voglhuber, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059863 · Cited by 108 · see citing works

Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy

Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 111 · see citing works

YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis

Yao, X., Li, W., Li, L., Li, M., Zhao, Y., Fang, D., Zeng, X., & Luo, Z. Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04711-1 · Cited by 101 · see citing works

Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis

Zeng, X., Shi, G., He, Q., & Zhu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00268-9 · Cited by 76 · see citing works

HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells

Petri, B. J., Piell, K. M., Whitt, G. C. S., Wilt, A. E., Poulton, C. C., Lehman, N. L., Clem, B. F., Nystoriak, M. A., Wysoczynski, M., & Klinge, C. M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.015 · Cited by 65 · see citing works

Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα

Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 64 · see citing works

PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 64 · see citing works

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65 · see citing works

Highlights on U.S. FDA-approved halogen-containing drugs in 2024

Ali, S., Tian, X., Meccia, S. A., & Zhou, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117380 · Cited by 63 · see citing works

Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis

Park, H., Brown, S. R., & Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145040 · Cited by 56 · see citing works

Unbiased Detection of Driver Mutations in Extramammary Paget Disease

Ishida, Y., Kakiuchi, N., Yoshida, K., Inoue, Y., Irie, H., Kataoka, T. R., Hirata, M., Funakoshi, T., Matsushita, S., Hata, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3205 · Cited by 55 · see citing works

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 54 · see citing works

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics

Xiao, W., Zhang, G., Chen, B., Chen, X., Wen, L., Lai, J., Li, X., Li, M., Liu, H., Liu, J. L., et al. (2021) · Journal of Cancer · doi:10.7150/jca.52993 · Cited by 53 · see citing works

Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers

Miranda, F., Prazeres, H., Mendes, F., Martins, D. F., & Schmitt, F. C. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06863-3 · Cited by 53 · see citing works

The Importance of Phosphoinositide 3-Kinase in Neuroinflammation

Wright, B., King, S. P., & Suphioglu, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111638 · Cited by 54 · see citing works

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance

Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 48 · see citing works

Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function

Rouhimoghadam, M., Lu, A. S., Salem, A. K., & Filardo, E. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.591217 · Cited by 49 · see citing works

AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis

Sun, Z., Jiang, Q., Gao, B. X., Zhang, X., Bu, L., Wang, L., Lin, Y., Xie, W., Li, J., & Guo, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3407 · Cited by 45 · see citing works

Targeting the RAS upstream and downstream signaling pathway for cancer treatment

Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 47 · see citing works

Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development

Font-Díaz, J., Jiménez‐Panizo, A., Caelles, C., Vivanco, M. D., Pérez, P., Aranda, A., Estébanez‐Perpiñá, E., Castrillo, A., Ricote, M., & Valledor, A. F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.007 · Cited by 45 · see citing works

Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression

Wang, M., Lan, S., Zhang, W., Jin, Q., Du, H., Sun, X., He, L., Meng, X., Su, L., & Liu, G. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s449887 · Cited by 44 · see citing works

Quinazolinones as Potential Anticancer Agents: Synthesis and Action Mechanisms

Deng, Z., Li, J., Zhu, P., Wang, J., Kong, Y., Hu, Y., Cai, J., & Dong, C. (2025) · Biomolecules · doi:10.3390/biom15020210 · Cited by 43 · see citing works

PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

Zhang, M., Jang, H., & Nussinov, R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0911 · Cited by 41 · see citing works

Sea Cucumber Intestinal Peptide Induces the Apoptosis of MCF-7 Cells by Inhibiting PI3K/AKT Pathway

Wei, W., Fan, X.-M., Jia, S., Zhang, X., Zhang, Z., Zhang, X.-J., Zhang, J.-X., & Zhang, Y. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.763692 · Cited by 43 · see citing works

Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges

He, H., Shao, X., Li, Y., Gihu, R., Xie, H., Zhou, J., & Yan, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.675675 · Cited by 41 · see citing works

Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial‐mesenchymal plasticity of human peritoneal mesothelial cells

Gao, L., Nie, X., Gou, R., Hu, Y., Dong, H., Li, X., & Lin, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16983 · Cited by 40 · see citing works

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 37 · see citing works

Molecular perspective on targeted therapy in breast cancer: a review of current status

Cetinkaya, B. D., & Avcı, Ç. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01749-1 · Cited by 38 · see citing works

Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer

Solís, M. C., Vethencourt, A., & Pernas, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01339-4 · Cited by 37 · see citing works

PI3KCA Mutations in Uterine Cervix Carcinoma

Voutsadakis, I. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020220 · Cited by 35 · see citing works

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

Dunn, S., Eberlein, C., Yu, J., Gris‐Oliver, A., Ong, S. H., Yelland, U., Cureton, N., Staniszewska, A. D., McEwen, R. K., Fox, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02482-9 · Cited by 36 · see citing works

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

Tao, Z., Li, T., Feng, Z., Liu, C., Shao, Y., Zhu, M., Gong, C., Wang, B., Cao, J., Wang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01023 · Cited by 35 · see citing works

Role of RhoC in cancer cell migration

Lou, Y., Jiang, Y., Liang, Z., Liu, B., Li, T. X., & Zhang, D. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02234-x · Cited by 34 · see citing works

Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway

Sharma, P. P., Khan, M. A., Najmi, A. K., Chaturvedi, S., & Akhtar, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01856-z · Cited by 34 · see citing works

Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer

Wylaź, M., Kaczmarska, A., Pajor, D., Hryniewicki, M., Gil, D., & Dulińska-Litewka, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115676 · Cited by 33 · see citing works

Biological effects and regulation of IGFBP5 in breast cancer

Dittmer, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.983793 · Cited by 32 · see citing works

Antitumor Activity In Vivo and Vitro of New Chiral Derivatives of Baicalin and Induced Apoptosis via the PI3K/Akt Signaling Pathway

Hou, Y., Pi, C., Feng, X., Wang, Y., Fu, S., Zhang, X., Zhao, L., & Wei, Y. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.018 · Cited by 29 · see citing works

A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer

Naeem, M., Iqbal, M. O., Khan, H., Ahmed, M. M., Farooq, M., Aadil, M. M., Jamaludin, M. I., Hazafa, A., & Tsai, W.-C. (2022) · Molecules · doi:10.3390/molecules27113412 · Cited by 29 · see citing works

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology Perspective

Liu, L., Graff, S. L., & Wang, Y. (2024) · Cancers · doi:10.3390/cancers17010016 · Cited by 27 · see citing works

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Gremke, N., Besong, I., Stroh, A., von Wichert, L., Witt, M., Elmshäuser, S., Wanzel, M., Fromm, M. F., Taudte, R. V., Schmatloch, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02180-4 · Cited by 28 · see citing works

Research update on the anticancer effects of buparlisib (Review)

Xing, J., Yang, J. H., Gu, Y., & Yi, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12527 · Cited by 27 · see citing works

Hypoxia Induced by Cobalt Chloride Triggers Autophagic Apoptosis of Human and Mouse Drug‐Resistant Glioblastoma Cells through Targeting the PI3K‐AKT‐mTOR Signaling Pathway

Lee, Y., Cherng, Y., Yang, S., Liu, S., Chen, T.-L., & Chen, R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5558618 · Cited by 27 · see citing works

Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFβ/PI3K/AKT pathways

Labrèche, C., Cook, D. P., Abou‐Hamad, J., Pascoal, J., Pryce, B. R., Al‐Zahrani, K. N., & Sabourin, L. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01487-8 · Cited by 27 · see citing works

Tandem Suzuki Coupling/Intramolecular Oxetane Ring Opening to Form Polycyclic Ring Systems

DeRatt, L. G., Lawson, E. C., Kumar., K., V, Hwang, S. S., DesJarlais, R. L., & Kuduk, S. D. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01899 · Cited by 27 · see citing works

Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities

Zhang, B., Leung, P., Cho, W. C. S., Wong, C. K., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06144-8 · Cited by 26 · see citing works

Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells

Andreidesz, K., Kőszegi, B., Kovács, D., Vántus, V. B., Gallyas, F., & Kovács, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042056 · Cited by 26 · see citing works

Enhanced VEGF secretion and blood–brain barrier disruption: Radiation‐mediated inhibition of astrocyte autophagy via PI3K‐AKT pathway activation

Zhang, S., Li, M., Qiu, Y., Wu, J., Xu, X., Ma, Q., Zheng, Z., Lu, G., Deng, Z., & Huang, H. (2023) · Glia · doi:10.1002/glia.24491 · Cited by 26 · see citing works

Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity

Javadian, P., Washington, C. R., Mukasa, S., & Benbrook, D. M. (2021) · Cancers · doi:10.3390/cancers13081900 · Cited by 24 · see citing works

Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences

Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 24 · see citing works

Targeting HDACs for diffuse large B-cell lymphoma therapy

Wu, C., Song, Q., Gao, S. W., & Wu, S.-L. (2024) · Scientific Reports · doi:10.1038/s41598-023-50956-x · Cited by 21 · see citing works

Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET/CT

Kwon, H. W., Lee, J. H., Pahk, K., Park, K. H., & Kim, S. (2021) · Cancer Imaging · doi:10.1186/s40644-021-00424-4 · Cited by 21 · see citing works

CTGF, FN1, IL-6, THBS1, and WISP1 genes and PI3K-Akt signaling pathway as prognostic and therapeutic targets in gastric cancer identified by gene network modeling

Khoshdel, F., Mottaghi-Dastjerdi, N., Yazdani, F., Salehi, S., Ghorbani, A., Montazeri, H., Soltany‐Rezaee‐Rad, M., & Goodarzy, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01225-4 · Cited by 20 · see citing works

Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer

Leenhardt, F., Alexandre, M., & Jacot, W. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873952 · Cited by 20 · see citing works

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

Mishra, R., Yuan, L., Patel, H. M., Karve, A. S., Zhu, H., White, A., Alanazi, S., Desai, P. B., Merino, E. J., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042088 · Cited by 20 · see citing works

Growth Hormone Modulation of Hepatic Epidermal Growth Factor Receptor Signaling

González, L., Díaz, M. E., Miquet, J. G., Sotelo, A. I., & Dominici, F. P. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.004 · Cited by 20 · see citing works

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

Cheng, G. J., Leung, E. Y., & Singleton, D. C. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00084 · Cited by 22 · see citing works

Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway

Zhou, W., Juan, W., tong, D., Juan, L. X., Yi, L., Huang, J., Guan, X., Xiang, L. G., Jie, H. M., & Chen, X. (2022) · Food & Function · doi:10.1039/d2fo02387c · Cited by 20 · see citing works

Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation

de Godoy, B. L. V., Moschetta‐Pinheiro, M. G., Chuffa, L. G. D. A., Ponde, N. F., Reiter, R. J., Colombo, J., & Zuccari, D. A. P. D. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121708 · Cited by 20 · see citing works

A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer

Meng, D., Zhao, X., Yang, Y. C., Navickas, A., Helland, C., Goodarzi, H., Singh, M., & Bandyopadhyay, S. (2023) · Oncogene · doi:10.1038/s41388-023-02737-z · Cited by 20 · see citing works

The mechanism of AKT activation in cancer

Meng, F., Li, H., Wang, Y., Zheng, Z., & Chen, Y. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100046 · Cited by 19 · see citing works

Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity

Soong, T. R., Dillon, D. A. R., Rice-Stitt, T. L., Wieczorek, T. J., Baker, G. M., Darvishian, F., Collins, L. C., Lester, S. C., Schnitt, S. J., & Harrison, B. T. (2022) · Modern Pathology · doi:10.1038/s41379-022-01084-w · Cited by 19 · see citing works

The prognostic significance of tumor-infiltrating lymphocytes in cervical cancer

He, M., Wang, Y., Zhang, G., Cao, K., Yang, M., & Liu, H. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e32 · Cited by 19 · see citing works

A New Chalcone Derivative C49 Reverses Doxorubicin Resistance in MCF-7/DOX Cells by Inhibiting P-Glycoprotein Expression

Wang, T., Dong, J., Xu, Y., Wen, H., Wu, L., Liu, J., Sui, H. X., & Deng, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653306 · Cited by 19 · see citing works

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

Damane, B. P., Hull, R., Bida, M., Durandt, C., Mulaudzi, T. V., Chatziioannou, A. A., & Dlamini, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030682 · Cited by 20 · see citing works

Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer

Xie, J., Kusnadi, E. P., Furic, L., & Selth, L. A. (2021) · Cancers · doi:10.3390/cancers13133254 · Cited by 18 · see citing works

Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors

Wang, Y., Liu, Y., Ge, T., Tang, J., Wang, S., Gao, Z., Chen, J., Xu, J., Gong, P., Zhao, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106211 · Cited by 18 · see citing works

HER2-Positive Breast Cancer Treatment and Resistance

Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 21 · see citing works

Development of PI3Kα inhibitors for tumor therapy

Jia, W., Luo, S., Guo, H. W., & Kong, D. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2132293 · Cited by 17 · see citing works

A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer

Dubey, R., Sharma, A., Gupta, S., Gupta, G. D., & Asati, V. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107077 · Cited by 17 · see citing works

PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging

Duggan, M. R., Weaver, M. W., & Khalili, K. (2021) · Aging · doi:10.18632/aging.202459 · Cited by 15 · see citing works

Breast Cancer Prognosis Prediction and Immune Pathway Molecular Analysis Based on Mitochondria-Related Genes

Luo, W., Han, Y., Li, X., Liu, Z., Meng, P., & Wang, Y. (2022) · Genetics Research · doi:10.1155/2022/2249909 · Cited by 16 · see citing works

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative

Ascione, L., Zagami, P., Nicolò, E., Crimini, E., Curigliano, G., & Criscitiello, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111793 · Cited by 16 · see citing works

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

Gebbia, V., Valerio, M. R., Firenze, A., & Vigneri, P. G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1781814 · Cited by 16 · see citing works

Combined endocrine and targeted therapy in luminal breast cancer

Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 16 · see citing works

Nuclear Mechanisms Involved in Endocrine Resistance

Dittmer, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736597 · Cited by 16 · see citing works

Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer

Colombo, J., Moschetta‐Pinheiro, M. G., Novais, A. A., Stoppe, B. R., Bonini, E. D., Gonçalves, F. M., Fukumasu, H., Coutinho, L. L., Chuffa, L. G. D. A., & Zuccari, D. A. P. D. C. (2021) · Cancers · doi:10.3390/cancers13205233 · Cited by 16 · see citing works

ELK1 / KIFC1 axis promotes breast cancer cell proliferation by regulating glutathione metabolism

Yang, B., Wang, H., Jian, X., Chen, W., & Chen, W. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15710 · Cited by 16 · see citing works

GPRC5A Is a Negative Regulator of the Pro-Survival PI3K/Akt Signaling Pathway in Triple-Negative Breast Cancer

Yang, L., Zhao, S., Zhu, T., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624493 · Cited by 15 · see citing works

An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer

Yuan, J., Duan, F., Zhai, W., Song, C., Wang, L., Xia, W., Hua, X., Yuan, Z., Bi, X., & Huang, J. (2021) · International Journal of Women s Health · doi:10.2147/ijwh.s334756 · Cited by 15 · see citing works

Integrative strategies in breast cancer therapy: Conventional approaches, emerging advances, and future challenges

Eapen, J. V., George, P. R., Thomas, S., & Antony, J. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100012 · Cited by 14 · see citing works

Extracellular Vesicles Induce an Aggressive Phenotype in Luminal Breast Cancer Cells Via PKM2 Phosphorylation

Kang, S. Y., Lee, E. J., Byun, J. W., Han, D., Choi, Y., Hwang, D. W., & Lee, D. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785450 · Cited by 14 · see citing works

PI3K Inhibitors in Breast Cancer Therapy

Ellis, H., & Ma, C. X. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0846-7 · Cited by 220 · see citing works

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance

Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 48 · see citing works

Alpelisib to treat breast cancer

Copur, M. S. (2020) · Drugs of today · doi:10.1358/dot.2020.56.6.3137526 · Cited by 25 · see citing works

Recent Advances in PI3K Inhibitor HR+/HER2- Advanced Breast Cancer, A Review ArticlePreprint

Mukherjee, D., & Mukherjee, K. K. (2020) · SSRN Electronic Journal

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

The Society of Clinical Research of Oncology Medications of China Anticancer Association, & Breast Cancer Expert Committee of National Cancer Quality Control Center (2022) · Cancer Innovation · doi:10.1002/cai2.10 · Cited by 9 · see citing works